Non-Small-Cell Lung Cancer | Pharmacor | G7 | 2014
Last Updated 20 October 2014
Biomarker- and histology-driven prescribing is standard practice in the treatment of non-small-cell lung cancer (NSCLC) across the major pharmaceutical markets. The treatment of NSCLC patients including that of molecularly defined subpopulations continues to evolve, driven by the development of novel agents and increasingly, associated biomarkers and companion diagnostics. Codeveloping a drug and a companion diagnostic is one of the most promising avenues for commercial success. Several underserved areas of high unmet need offer significant commercial opportunity for innovative agents.
Related Market Assessment Reports
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC (US/EU)
Approximately 20% of nonsquamous NSCLC in Western patients is driven by mutations in EGFR, and as such is treated predominantly with agents targeting those alterations. The market is currently…
Report
Non-Small-Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Non-Small-Cell Lung Cancer (US)
Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. In 2024, Imfinzi…
Report
Non-Small-Cell Lung Cancer – Current Treatment – Treatment Sequencing – Non-Small-Cell Lung Cancer (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
